DNAH5 mutations are a common cause of primary ciliary Dyskinesia with outer dynein arm defects
Funding The authors declare financial support was received for the research, authorship, and/or publication of this article
Tirzepatide is a GIP and GLP-1 receptor antagonist that should be approved for weight loss this year by the FDA
This small molecule is a potent and selective non-competitive inhibitor of NNMT
If the primary outcome showed superiority, secondary outcomes were tested in a pre-specified order to control the type I errors Total eGFR slope (the annual rate of change in eGFR from randomization to the end of the trial) Major cardiovascular events (a composite of nonfatal MI, nonfatal stroke, or death from CV causes) Death from any cause The other supportive secondary outcomes are shown in the figure below
However, what they all have in common, is a combination of psychological and physical symptoms